Downregulation of Plasma miR-215 in Chronic Myeloid Leukemia Patients with Successful Discontinuation of Imatinib

By Ohyashiki Kazuma   Umezu Tomohiro   Katagiri Seiichiro   Kobayashi Chiaki   Azuma Kenko   Tauchi Tetsuzo   Okabe Seiichi   Fukuoka Yutaka   Ohyashiki Junko H.  

International Journal of Molecular Sciences, Vol. 17, Iss. 4, 2016-04 ,pp. : 570-570

MDPI

Access to resources Recommend Favorite

p53 Gene (NY-CO-13) Levels in Patients with Chronic Myeloid Leukemia: The Role of Imatinib and Nilotinib

By Al-kuraishy Hayder M.   Al-Gareeb Ali I.   Al-Buhadilly Ali K.  

Diseases, Vol. 6, Iss. 1, 2018-01 ,pp. : 13-13

MDPI

Access to resources Recommend Favorite

Proteome Changes Induced by Imatinib and Novel Imatinib Derivatives in K562 Human Chronic Myeloid Leukemia Cells

By Arvaniti Katerina   Papadioti Anastasia   Kinigopoulou Maria   Theodorou Vassiliki   Skobridis Konstantinos   Tsiotis Georgios  

Proteomes, Vol. 2, Iss. 3, 2014-07 ,pp. : 363-381

MDPI

Access to resources Recommend Favorite

Distinct Dasatinib-Induced Mechanisms of Apoptotic Response and Exosome Release in Imatinib-Resistant Human Chronic Myeloid Leukemia Cells

By Liu Juan   Zhang Yujing   Liu Aichun   Wang Jinghua   Li Lianqiao   Chen Xi   Gao Xinyu   Xue Yanming   Zhang Xiaomin   Liu Yao  

International Journal of Molecular Sciences, Vol. 17, Iss. 4, 2016-04 ,pp. : 531-531

MDPI

Access to resources Recommend Favorite

Pharmacogenetics of BCR/ABL Inhibitors in Chronic Myeloid Leukemia

By Polillo Marialuisa   Galimberti Sara   Baratè Claudia   Petrini Mario   Danesi Romano   Di Paolo Antonello  

International Journal of Molecular Sciences, Vol. 16, Iss. 9, 2015-09 ,pp. : 22811-22829

MDPI

Access to resources Recommend Favorite